Rps Medical Technology (Beijing) Co Ltd

Primary objective: To demonstrate improved clinical efficacy of Tisotumab vedotin compared to chemotherapy in participants with 2L-3L cervical cancer Secondary objectives: 1. To evaluate the improved clinical efficacy of Tisotumab vedotin compared to chemotherapy in participants with 2L-3L cervical cancer 2. To demonstrate improved antitumor activity of Tisotumab vedotin compared to chemotherapy in participants with 2L-3L cervical cancer 3. To characterize the antitumor response of Tisotumab vedotin and chemotherapy in participants with 2L-3L cervical cancer 4. To evaluate the safety and tolerability of Tisotumab vedotin 5. To evaluate health-related quality of life (HRQOL) 6. To evaluate the pharmacokinetics (PK) and immunogenicity of Tisotumab vedotin

The primary objective is to evaluate the efficacy of cabozantinib combined with atezolizumab compared with sorafenib in subjects with advanced HCC who have not received prior systemic anticancer therapy. The secondary objective is to evaluate the activity of cabozantinib compared with sorafenib alone in this patient population.